uniQure (QURE) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.78

Estimate

-$0.82

Surprise

+4.3%

Revenue (period 2026-09-30)

$5.2M

Score today

5.2/10

Revenue source: xbrl.

uniQure (QURE) reported a narrower loss than forecast — adjusted EPS of -$0.78 against the -$0.82 estimate (a 4.3% beat on a still-unprofitable quarter).

• uniQure Reports Third-Quarter 2026 Financial Results — fiscal.ai, 2026-11-04
• uniQure Q3 2026 Earnings Call Transcript — benzinga, 2026-11-04
• uniQure Q3 EPS $(0.88) Beats $(0.92) Estimate, Sales $5.200M Miss $6.178M Estimate — benzinga, 2026-11-04

TrendMatrix currently rates QURE Sell at 5.2/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +4.3% surprise compares with a -1.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$23.03

Price target

$52.71

Stop

$21.42

Upside to target

+128.9%

Reward-to-risk

9.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.60B

P/E (fwd)

-7.8

52-week range

$8.73–$51.72

Off 52-week high

55.5%

RSI (14)

52

Volume vs avg

1.38×

Score today

5.2/10